Three Rivers gets expanded rights to Infergen
Three Rivers Pharmaceuticals is to acquire expanded commercial rights to the hepatitis C drug Infergen (interferon-alpha; Marketletter January 21) from fellow-US firm Amgen.
Three Rivers currently has rights to the drug in the USA and Canada, but will now immediately gain the rights to all markets except Japan, aside from China, where the rights are forthcoming as of March 31, 2009. The firm is currently seeking marketing partners for the product outside of the USA.
Infergen, or consensus interferon, is a unique, bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the USA in 1997. The product is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and /or the presence of HCV RNA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze